Evolution of Structure-guided Drug Design Strategies Targeting Mutations in Codon 12 of KRAS

KRAS G12 mutations drive aggressive cancers. Once considered undruggable, several strategies evolved in the last decade to target OFF and ON states. Approval of inhibitors and the growing pipeline offer great hope to patients.